Gentile Pietro, Casella Donato, Palma Enza, Calabrese Claudio
Department of Surgical Science, Plastic and Reconstructive Surgery Unit, University of Rome Tor Vergata, 00133 Rome, Italy.
The Oncologic and Reconstructive Surgery Breast Unit, Oncology Department, Careggi University Hospital, 50134 Florence, Italy.
J Clin Med. 2019 Apr 12;8(4):504. doi: 10.3390/jcm8040504.
The areas in which Stromal Vascular Fraction cells (SVFs) have been used include radiotherapy based tissue damage after mastectomy, breast augmentation, calvarial defects, Crohn's fistulas, and damaged skeletal muscle. Currently, the authors present their experience using regenerative cell therapy in breast reconstruction. The goal of this study was to evaluate the safety and efficacy of the use of Engineered Fat Graft Enhanced with Adipose-derived Stromal Vascular Fraction cells (EF-e-A) in breast reconstruction. 121 patients that were affected by the outcomes of breast oncoplastic surgery were treated with EF-e-A, comparing the results with the control group ( = 50) treated with not enhanced fat graft (EF-ne-A). The preoperative evaluation included a complete clinical examination, a photographic assessment, biopsy, magnetic resonance (MRI) of the soft tissue, and ultrasound (US). Postoperative follow-up took place at two, seven, 15, 21, 36 weeks, and then annually. In 72.8% ( = 88) of breast reconstruction treated with EF-e-A, we observed a restoration of the breast contour and an increase of 12.8 mm in the three-dimensional volume after 12 weeks, which was only observed in 27.3% ( = 33) of patients in the control group that was treated with EF-ne-A. Transplanted fat tissue reabsorption was analyzed with instrumental MRI and US. Volumetric persistence in the study group was higher (70.8%) than that in the control group (41.4%) ( < 0.0001 vs. control group). The use of EF-e-A was safe and effective in this series of treated cases.
基质血管成分细胞（SVFs）的应用领域包括乳房切除术后基于放疗的组织损伤、隆胸、颅骨缺损、克罗恩瘘和受损骨骼肌。目前，作者介绍了他们在乳房重建中使用再生细胞疗法的经验。本研究的目的是评估在乳房重建中使用脂肪来源基质血管成分细胞增强的工程脂肪移植（EF-e-A）的安全性和有效性。121例受乳房肿瘤整形手术结果影响的患者接受了EF-e-A治疗，并将结果与未增强脂肪移植（EF-ne-A）治疗的对照组（n = 50）进行比较。术前评估包括全面的临床检查、摄影评估、活检、软组织磁共振成像（MRI）和超声检查（US）。术后随访在第2、7、15、21、36周进行，之后每年进行一次。在接受EF-e-A治疗的乳房重建中，72.8%（n = 88）的患者在12周后乳房轮廓恢复，三维体积增加了12.8毫米，而在接受EF-ne-A治疗的对照组中，只有27.3%（n = 33）的患者出现这种情况。通过仪器MRI和US分析移植脂肪组织的吸收情况。研究组的体积保留率（70.8%）高于对照组（41.4%）（与对照组相比，P < 0.0001）。在这一系列治疗病例中，使用EF-e-A是安全有效的。
